Prescription monitoring program

Last updated

In the United States, prescription monitoring programs (PMPs) or prescription drug monitoring programs (PDMPs) are state-run programs which collect and distribute data about the prescription and dispensation of federally controlled substances and, depending on state requirements, other potentially abusable prescription drugs. PMPs are meant to help prevent adverse drug-related events such as opioid overdoses, drug diversion, and substance abuse by decreasing the amount and/or frequency of opioid prescribing, and by identifying those patients who are obtaining prescriptions from multiple providers (i.e., "doctor shopping") or those physicians overprescribing opioids. [1] [2]

Contents

Most US health care workers support the idea of PMPs, which intend to assist physicians, physician assistants, nurse practitioners, dentists and other prescribers, the pharmacists, chemists and support staff of dispensing establishments. The database, whose use is required by State law, typically requires prescribers and pharmacies dispensing controlled substances to register with their respective state PMPs and (for pharmacies and providers who dispense from their offices) to report the dispensation of such prescriptions to an electronic online database. The majority of PMPs are authorized to notify law enforcement agencies or licensing boards or physicians when a prescriber, or patients receiving prescriptions, exceed thresholds established by the state or prescription recipient exceeds thresholds established by the State. [3] All states have implemented PDMPs, although evidence for the effectiveness of these programs is mixed. [4] [5] While prescription of opioids has decreased with PMP use, overdose deaths in many states have actually increased, with those states sharing data with neighboring jurisdictions or requiring reporting of more drugs experiencing highest increases in deaths. [6] This may be because those declined opioid prescriptions turn to street drugs, whose potency and contaminants carry greater overdose risk. [6]

History

Prescription drug monitoring programs, or PDMPs, are an example of one initiative proposed to alleviate effects of the opioid crisis. [1] The programs are designed to restrict prescription drug abuse by limiting a patient's ability to obtain similar prescriptions from multiple providers (i.e. “doctor shopping”) and reducing diversion of controlled substances. This is meant to reduce risk of fatal overdose caused by high doses of opioids or interactions between opioids and benzodiazepenes, and to enable better decision making on the part of healthcare providers who may be unaware of a patient's prescription drug use, history or other prescriptions. [7] [8]

PDMPs have been implemented in state legislations since 1939 in California, a time before electronic medical records, though implementation increased with s awareness of overprescribing of opioids and overdose. [9] [3] A later New York state program was struck down by the U.S. Supreme Court in Whalen v. Roe . [10] But, by 2019, 49 states, the District of Columbia, and Guam had enacted PDMP legislation. [11] In 2021 Missouri, the last State to not use a PMP, adopted legislation to create one. [12] [13]

PMPs are constantly being updated to increase speed of data collection, sharing of data across States, and ease of interpretation. This is being done by integrating PDMP reports with other health information technologies such as health information exchanges (HIE), electronic health record (EHR) systems, and/ or pharmacy dispensing software systems. [14] One program that has been implemented in nine states is called the PDMP Electronic Health Records Integration and Interoperability Expansion, also known as PEHRIIE. Another software, marketed by Bamboo Health and integrated with PMPs in 43 states, uses an algorithm to track factors thought to increase risk of diversion, abuse or overdose, and assigns patients a three digit score based on presumed indicators of risk. [15] While some studies have suggested that PDMP-HIT integration and sharing of interstate data brings benefits such as reduced opioid-related inpatient morbidity, [16] others have found no or negative impact on mortality compared to states without PMP data sharing. [6] Patient and media reports suggest need for testing and evaluation of algorithmic software used to score risk, with some patients reporting denial of prescriptions without c explanation or clarity of data. [15]

Goals

Most health care workers support PMPs [17] which intend to assist physicians, physician assistants, nurse practitioners, dentists and other prescribers, the pharmacists, chemists and support staff of dispensing establishments, as well as law-enforcement agencies. The collaboration supports the legitimate medical use of controlled substances while limiting their abuse and diversion. Pharmacies dispensing controlled substances and prescribers typically must register with their respective state PMPs and (for pharmacies and providers who dispense controlled substances from their offices) report the dispensation to an electronic online database. Some pharmacy software can submit these reports automatically to multiple states. [18]

Usage

List of programs by state

State NameState CodeFormatMethodReporting AgencySchedules MonitoredDocumentationState FrequencyData Retention
AlaskaAKASAP 2009 v4.1sFTPAppriss:855-525-47672 - 5 Source Monthly2 Source
AlabamaALASAP 2007 v4.0sFTPHealth Information Design Phone: 334.502.32622 - 5 Source Daily ?
ArkansasARASAP 2011 v4.2sFTPHealth Information Design Phone: 334.502.3262 ? ?Weekly ?
ArizonaAZASAP 2011 v4.2sFTPHealth Information Design Phone: 334.502.32622 - 4 + Carisoprodol Source DailyAdult 6 / Minor 3 Source
CaliforniaCAASAP 2009 v4.1sFTPAtlantic Associates, Inc Phone: 800.539.33702 - 4 Source Weekly3 Source
ColoradoCOASAP 2012 v4.2sFTPHealth Information Design Phone: 334.502.32622 - 5 Source Bi-Weekly ?
ConnecticutCTASAP 4.2FTPsAppriss:855-525-47672 - 5 Source Bi-Weekly ?
District of ColumbiaDCASAP 4.2 ? ? ? ? ? ?
DelawareDEASAP 2011 v4.2sFTPHealth Information Design Phone 334.502.32622 - 5 Source Daily ?
FloridaFLASAP 2009 v4.2sFTPHealth Information Design Phone: 334.502.32622 - 4 Source Weekly ?
GeorgiaGAASAP 2011 V4.2 ?Appriss:855-525-4767 ? ? ?1 Source
HawaiiHIASAP 2009 v4.2Web PortalAppriss:855-525-47672 - 5 + Carisoprodol Source Weekly https://hipdmpreporting.hidinc.com/
IdahoIDASAP 2009 v4.1sFTPAppriss:855-525-47672 - 5 Source Weekly ?
IllinoisILASAP 2007 v4.0sFTPAtlantic Associates, Inc Phone: 800.539.33702 - 5 Source Weekly2 Source
IndianaINASAP 2007 v4.2FTPsINSPECT Phone: 317.234.4458 Phone:866.683.24762 - 5 + Carisoprodol (SOMA) Daily ?
IowaIAASAP v4.1FTPsOptimum Technology, Inc Phone: 866.683.24762 - 4 Source BWeekly4 Source
KansasKSASAP 2009 v4.1sFTPAppriss:855-525-47672 - 4 + Drugs of Concern Source Daily ?
KentuckyKYASAP 2009 v4.1sFTPHealth Information Design Phone: 334.502.32622 - 5 + Carisoprodol, Tramadol Source Daily5 Source
LouisianaLAASAP 4.2sFTPAppriss:855-525-47672 - 5 + Tramadol, Butalibtal, Carisoprodol, Ephedrine, Pseudoephedrine, PPA Source Weekly ?
MassachusettsMAASAP 2009 v4.1sFTPAppriss:855-525-47672 - 5 Source Weekly ?
MarylandMDASAP 2011 V4.2sFTPHealth Information Design Phone: 334.502.32622 - 4 Source Weekly ?
MaineMEASAP 2009 v4.1sFTPAppriss:855-525-47672 - 4 Source Bi-Weekly6 Source
MichiganMIASAP 2009 v4.1Web PortalMichigan Automated Prescription System (MAPS) Source 2 - 5 Source Bi-Weekly ?
MinnesotaMNASAP 2007 v4.0sFTPHealth Information Design Phone: 334.502.32622 - 4 + Codeine containing cough syrups that are schedule 5 federally are schedule 3 in MN; Human growth hormones are schedule 3 in MN. Source Daily1 Source
MissouriMOASAP 4.2 ? ? ? ? ?3 Source
MississippiMSASAP 2005 v3.0sFTPAppriss:855-525-47672 - 5 + Butalbital, Carisoprodol, Soma, Tramadol Powder, Ultracet, Ultram ER, Ryzolt ER. Weekly ?
MontanaMTASAP 4.2sFTPMontana Prescription Drug Registry  ? ?Weekly ?
North CarolinaNCASAP 4.2sFTPHealth Information Design Phone: 334.502.32622 - 5 Source Weekly6 Source
North DakotaNDASAP 2009 v4.1sFTPHealth Information Design Phone: 334.502.32622 - 5 + Tramadol, Carisoprodol Source Daily ?
NebraskaNEASAP 4.2 ? ? ? ? ? ?
New HampshireNHASAP 4.2sFTPAppriss:855-525-47672 - 5 + Tramadol, Carisoprodolnhpdmpreporting.hidinc.comDaily ?
New JerseyNJASAP 2009 v4.1sFTPAppriss:855-525-47672 - 5 and HCG Weekly ?
New MexicoNMASAP 2009 v4.1Web PortalAppriss:855-525-47672 - 4 + Butalbital (Fioricet), Carisoprodol (Soma), Dezocine (Dalgan), Flunitrazepam (Rohypnol), Nalbuphine (Nubain), Pseudoephedrine (Sudafed) Source Weekly ?
NevadaNVASAP 2005 v3.0sFTPAppriss:855-525-47672 - 4 + Carisoprodol Source Weekly ?
New YorkNYASAP 2007 v4.0Web PortalNew York (DOH & BNDD) Phone: 866.811.79572 - 5 + Chorionic Gonadotropin, HCG Source Daily5 Source
OhioOHASAP 2009 v4.1sFTPOhio Automated Rx Reporting System (OARRS) Phone: 614.466.41432 - 5 + Carisoprodol, Tramadol Source Daily2 Source
OklahomaOKASAP 2019 v4.2bWeb ServiceAppriss:855-525-47672 - 5 + Tramadol Source Within 5 Minutes ?
OregonORASAP 2009 v4.1sFTPHealth Information Design Phone: 334.502.32622 - 4 ?Weekly3 Source
PennsylvaniaPAASAP 2007 v4.0FTPsAppriss:855-525-47672 + ephedrine, pseudoephedrine, phenylpropanolamine, PSE ?Monthly ?
Rhode IslandRIASAP 4.2Web PortalPrescription Monitoring Program (PMP) Phone: 401.222.28402 - 3 Source Monthly ?
South CarolinaSCASAP 4.2sFTPAppriss:855-525-47672 - 4 Source Monthly ?
South DakotaSDASAP 2009 v4.1sFTPAppriss:855-525-47672 - 4 ?Weekly ?
TennesseeTNASAP 2009 v4.1FTPsOptimum Technology, Inc Phone: 866.683.24762 - 5 Source Bi-Weekly ?
TexasTXASAP 2009 v4.1FTPsAppriss:855-525-47672 - 5 + Carisoprodol Source Bi-Weekly1 Source
UtahUTASAP 4.2Web PortalUtah Controlled Substance Database Program Phone: 801.530.62322 - 5 + butalbital w/acetaminophen Source DailyUCA 58-37f
VirginiaVAASAP 2009 v4.1FTPsAppriss:855-525-47672 - 4 Source Bi-Weekly ?
VermontVTASAP 2005 v3.0sFTPAppriss:855-525-47672 - 4 ?Weekly6 Source
WashingtonWAASAP 2011 v4.2sFTPHealth Information Design Phone: 334.502.32622 - 5 Source Weekly ?
WisconsinWIASAP 2011 v4.2 ? ?2-5 + Tramadol ? ? ?
West VirginiaWVASAP 4.2Web PortalWest Virginia Board of Pharmacy2 -4 Source  ? ?
WyomingWYASAP 4.2sFTPAtlantic Associates, Inc. Phone: 800.539.33702 - 4 + Tramadol, Carisoprodol Source Weekly ?

Software systems

NarxCare is a prescription drug monitoring program (PDMP) run by Bamboo Health. [19] [20] Bamboo Health was formerly known as Appriss. [19] It is widely used across the United States by pharmacies including Rite Aid as well as those at Walmart and Sam’s Club. The NarxCare software allows doctors to view data about a patient, combining data from the prescription registries of various U.S. states to make the registries interoperable nationally. It also uses machine learning to generate an "Overdose Risk Score" that potentially includes EMS and criminal justice data; these scores have been criticized by researchers and patient advocates for the lack of transparency in the process as well as the potential for disparate treatment of women and minority groups. [20]

Advertised as an "analytics tool and care management platform", the NarxCare software allows doctors to view data about a patient including how many pharmacies they have visited and the combinations of medication they are prescribed. [21] It combines data from the prescription registries of various U.S. states, making the registries interoperable nationally. [22] [23] It additionally uses machine learning to generate various three-digit "risk scores" and an overall "Overdose Risk Score", collectively referred to as Narx Scores, [24] in a process that potentially includes EMS and criminal justice data [21] as well as court records. [25]

Controversy

Many doctors and researchers support the idea of PDMPs as a tool in combatting the opioid epidemic. Opioid prescribing, opioid diversion and supply, opioid misuse, and opioid-related morbidity and mortality are common elements in data entered into PDMPs. [9] Prescription Monitoring Programs are purported to offer economic benefits for the states who implement them by decreasing overall health care costs, lost productivity, and investigation times. [11]

However, there are many studies that conclude the impact of PDMPs is unclear. [9] While use of PMPs has been accompanied by decrease in opioid prescribing, few analyses consider corresponding use of street opioids, extramedical use, or diversion, which might provide a more holistic method for evaluation of PMP intent and efficacy. Evidence for PDMP impact on fatal overdoses is decidedly mixed, with multiple studies finding increased overdose rates in some states, decreases in others, or no clear impact. [5] [6] Interestingly, an increase in heroin overdoses after PDMP implementation has been commonly reported, presumably as denial of prescription opioids sends patients in search of street drugs. [26]

Narx Scores have been criticized by researchers and patient advocates for the lack of transparency in the generation process as well as the potential for disparate treatment of women and minority groups. [21] Writing in Duke Law Journal , Jennifer Oliva stated that "black-box algorithms" are used to generate the scores. [24]

Related Research Articles

<span class="mw-page-title-main">Methadone</span> Opioid medication

Methadone, sold under the brand names Dolophine and Methadose among others, is a synthetic opioid agonist used for chronic pain and also for opioid use disorder. It is used to treat chronic pain, and it is also used to treat addiction to heroin or other opioids. Prescribed for daily use, the medicine relieves cravings and removes withdrawal symptoms. Withdrawal management using methadone can be accomplished in less than a month, or it may be done gradually over a longer period of time, or simply maintained for the rest of the patient's life. While a single dose has a rapid effect, maximum effect can take up to five days of use. After long-term use, in people with normal liver function, effects last 8 to 36 hours. Methadone is usually taken by mouth and rarely by injection into a muscle or vein.

<span class="mw-page-title-main">Naloxone</span> Opioid receptor antagonist

Naloxone is an opioid antagonist: a medication used to reverse or reduce the effects of opioids. For example, it is used to restore breathing after an opioid overdose. Effects begin within two minutes when given intravenously, five minutes when injected into a muscle, and ten minutes as a nasal spray. Naloxone blocks the effects of opioids for 30 to 90 minutes.

<span class="mw-page-title-main">Over-the-counter drug</span> Medication available without a prescription

Over-the-counter (OTC) drugs are medicines sold directly to a consumer without a requirement for a prescription from a healthcare professional, as opposed to prescription drugs, which may be supplied only to consumers possessing a valid prescription. In many countries, OTC drugs are selected by a regulatory agency to ensure that they contain ingredients that are safe and effective when used without a physician's care. OTC drugs are usually regulated according to their active pharmaceutical ingredient (API) rather than final products. By regulating APIs instead of specific drug formulations, governments allow manufacturers the freedom to formulate ingredients, or combinations of ingredients, into proprietary mixtures.

<span class="mw-page-title-main">Medical prescription</span> Health-care communication from a physician to a pharmacist

A prescription, often abbreviated or Rx, is a formal communication from a physician or other registered healthcare professional to a pharmacist, authorizing them to dispense a specific prescription drug for a specific patient. Historically, it was a physician's instruction to an apothecary listing the materials to be compounded into a treatment—the symbol ℞ comes from the first word of a medieval prescription, Latin recipere, that gave the list of the materials to be compounded.

<span class="mw-page-title-main">Drug overdose</span> Use of an excessive amount of a drug

A drug overdose is the ingestion or application of a drug or other substance in quantities much greater than are recommended. Typically it is used for cases when a risk to health will potentially result. An overdose may result in a toxic state or death.

<span class="mw-page-title-main">Prescription drug</span> Medication legally requiring a medical prescription before it can be dispensed

A prescription drug is a pharmaceutical drug that is permitted to be dispensed only to those with a medical prescription. In contrast, over-the-counter drugs can be obtained without a prescription. The reason for this difference in substance control is the potential scope of misuse, from drug abuse to practicing medicine without a license and without sufficient education. Different jurisdictions have different definitions of what constitutes a prescription drug.

<span class="mw-page-title-main">Opioid use disorder</span> Medical condition

Opioid use disorder (OUD) is a substance use disorder characterized by cravings for opioids, continued use despite physical and/or psychological deterioration, increased tolerance with use, and withdrawal symptoms after discontinuing opioids. Opioid withdrawal symptoms include nausea, muscle aches, diarrhea, trouble sleeping, agitation, and a low mood. Addiction and dependence are important components of opioid use disorder.

Drug diversion is a medical and legal concept involving the transfer of any legally prescribed controlled substance from the individual for whom it was prescribed to another person for any illicit use. The definition varies slightly among different jurisdictions, but the transfer of a controlled substance alone usually does not constitute a diversion, since certain controlled substances that are prescribed to a child are intended to be administered by an adult, as directed by a medical professional. The term comes from the "diverting" of the drugs from their original licit medical purpose. In some jurisdictions, drug diversion programs are available to first time offenders of diversion drug laws, which "divert" offenders from the criminal justice system to a program of education and rehabilitation.

A methadone clinic is a medical facility where medications for opioid use disorder (MOUD) are dispensed-—historically and most commonly methadone, although buprenorphine is also increasingly prescribed. Medically assisted drug therapy treatment is indicated in patients who are opioid-dependent or have a history of opioid dependence. Methadone is a schedule II (USA) opioid analgesic, that is also prescribed for pain management. It is a long-acting opioid that can delay the opioid withdrawal symptoms that patients experience from taking short-acting opioids, like heroin, and allow time for withdrawal management. In the United States, by law, patients must receive methadone under the supervision of a physician, and dispensed through an Opioid Treatment Program (OTP) certified by the Substance Abuse and Mental Health Services Administration and registered with the Drug Enforcement Administration.

Electronic prescription is the computer-based electronic generation, transmission, and filling of a medical prescription, taking the place of paper and faxed prescriptions. E-prescribing allows a physician, physician assistant, pharmacist, or nurse practitioner to use digital prescription software to electronically transmit a new prescription or renewal authorization to a community or mail-order pharmacy. It outlines the ability to send error-free, accurate, and understandable prescriptions electronically from the healthcare provider to the pharmacy. E-prescribing is meant to reduce the risks associated with traditional prescription script writing. It is also one of the major reasons for the push for electronic medical records. By sharing medical prescription information, e-prescribing seeks to connect the patient's team of healthcare providers to facilitate knowledgeable decision making.

<span class="mw-page-title-main">Opioid overdose</span> Medical condition

An opioid overdose is toxicity due to excessive consumption of opioids, such as morphine, codeine, heroin, fentanyl, tramadol, and methadone. This preventable pathology can be fatal if it leads to respiratory depression, a lethal condition that can cause hypoxia from slow and shallow breathing. Other symptoms include small pupils, and unconsciousness, however its onset can depend on the method of ingestion, the dosage and individual risk factors. Although there were over 110,000 deaths in 2017 due to opioids, individuals who survived also faced adverse complications, including permanent brain damage.

The Ohio Automated Rx Reporting System (OARRS) is Ohio's state Prescription Monitoring Program (PMP) and is controlled by the Ohio State Board of Pharmacy. The law permitting the Board of Pharmacy to create the PMP was signed on March 18, 2005, and became effective January 1, 2006. The OARRS program began operation on October 2, 2006. The law is available to read in the Drug Laws of Ohio pages C-50 through C-54. The Ohio State Board of Pharmacy is responsible for collecting and verifying data for prescriptions that the Drug Enforcement Administration (DEA) classifies Schedule II-V as well as carisoprodol and tramadol prescriptions.

Electronic Prescriptions for Controlled Substances (EPCS) was originally a proposal for the DEA to revise its regulations to provide practitioners with the option of writing electronic prescriptions for controlled substances. These regulations would also permit pharmacies to receive, dispense, and archive these electronic prescriptions. These proposed regulations would be an addition to, not a replacement of, the existing rule.

<span class="mw-page-title-main">Pill mill</span> Illegal pain clinic

A pill mill is an illegal facility that resembles a regular pain clinic, but regularly prescribes painkillers (narcotics) without sufficient medical history, physical examination, diagnosis, medical monitoring, or documentation. Clients of these facilities usually receive prescriptions only against cash. Pill mills contribute to the opioid epidemic in the United States and are the subject of a number of legislative initiatives at the state level.

<span class="mw-page-title-main">Opioid epidemic in the United States</span> Ongoing overuse of opioid medication in the US

In the United States, the opioid epidemic is an extensive, ongoing overuse of opioid medications, both from medical prescriptions and illegal sources. The epidemic began in the United States in the late 1990s, according to the Centers for Disease Control and Prevention (CDC), when opioids were increasingly prescribed for pain management, resulting in a rise in overall opioid use throughout subsequent years. The great majority of Americans who use prescription opioids do not believe that they are misusing them.

<span class="mw-page-title-main">Drug disposal</span> Safe disposal of unused drugs

Drug disposal is the discarding of drugs. Individuals commonly dispose of unused drugs that remain after the end of medical treatment. Health care organizations dispose of drugs on a larger scale for a range of reasons, including having leftover drugs after treating patients and discarding of expired drugs. Failure to properly dispose of drugs creates opportunities for others to take them inappropriately. Inappropriate disposal of drugs can also cause drug pollution.

<span class="mw-page-title-main">Opioid epidemic</span> Deaths due to abuse of opioid drugs

The opioid epidemic, also referred to as the opioid crisis, is the rapid increase in the overuse, misuse/abuse, and overdose deaths attributed either in part or in whole to the class of drugs called opiates/opioids since the 1990s. It includes the significant medical, social, psychological, demographic and economic consequences of the medical, non-medical, and recreational abuse of these medications.

Opioid tapering is the reduction of opioid doses over time. Opioid tapering is typically done in people taking opioids for chronic pain. Tapering may be conducted in medically-supervised inpatient or outpatient settings.

<span class="mw-page-title-main">Prescription drug addiction</span> Medical condition

Prescription drug addiction is the chronic, repeated use of a prescription drug in ways other than prescribed for, including using someone else’s prescription. A prescription drug is a pharmaceutical drug that may not be dispensed without a legal medical prescription. Drugs in this category are supervised due to their potential for misuse and substance use disorder. The classes of medications most commonly abused are opioids, central nervous system (CNS) depressants and central nervous stimulants. In particular, prescription opioid is most commonly abused in the form of prescription analgesics.

In response to the surging opioid prescription rates by health care providers that contributed to the opioid epidemic in the United States, US states began passing legislation to stifle high-risk prescribing practices. These new laws fell primarily into one of the following four categories:

  1. Prescription Drug Monitoring Program (PDMP) enrollment laws: prescribers must enroll in their state's PDMP, an electronic database containing a record of all patients' controlled substance prescriptions
  2. PDMP query laws: prescribers must check the PDMP before prescribing an opioid
  3. Opioid prescribing cap laws: opioid prescriptions cannot exceed designated doses or durations
  4. Pill mill laws: pain clinics are closely regulated and monitored to minimize the prescription of opioids non-medically

References

  1. 1 2 Islam, M Mofizul; McRae, Ian S (2014). "An inevitable wave of prescription drug monitoring programs in the context of prescription opioids: pros, cons and tensions". BMC Pharmacol Toxicol. 15 (46): 46. doi: 10.1186/2050-6511-15-46 . PMC   4138942 . PMID   25127880.
  2. Sacco, Lisa N.; Duff, Johnathan H.; Sarata, Amanda K. (May 24, 2018). Prescription Drug Monitoring Programs (PDF). Washington, DC: Congressional Research Service. Retrieved 5 June 2018.
  3. 1 2 Substance Use and Mental Health Services Administration (2017). "Prescription Drug Monitoring Programs: A Guide For Health Professionals" (PDF). SAMSHA in Brief. 10 (1): 2.
  4. Rutkow, Lainie; Smith, Katherine C.; Lai, Alden Yuanhong; Vernick, Jon S.; Davis, Corey S.; Alexander, G. Caleb (2017). "Prescription drug monitoring program design and function: A qualitative analysis". Drug and Alcohol Dependence. 180: 395–400. doi:10.1016/j.drugalcdep.2017.08.040. PMID   28978492.
  5. 1 2 Ponnapalli, Aditya; Grando, Adela; Murcko, Anita; Wertheim, Pete (2018-12-05). "Systematic Literature Review of Prescription Drug Monitoring Programs". AMIA Annual Symposium Proceedings. 2018: 1478–1487. ISSN   1942-597X. PMC   6371270 . PMID   30815193.
  6. 1 2 3 4 Martins, Silvia S.; Ponicki, William; Smith, Nathan; Rivera-Aguirre, Ariadne; Davis, Corey S.; Fink, David S.; Castillo-Carniglia, Alvaro; Henry, Stephen G.; Marshall, Brandon D. L.; Gruenewald, Paul; Cerdá, Magdalena (December 2019). "Prescription drug monitoring programs operational characteristics and fatal heroin poisoning". The International Journal on Drug Policy. 74: 174–180. doi:10.1016/j.drugpo.2019.10.001. ISSN   1873-4758. PMC   6897357 . PMID   31627159.
  7. Department of Health. (n.d.). Retrieved from https://www.health.ny.gov/community/opioid_epidemic
  8. Baehren, David F.; Marco, Catherine A.; Droz, Danna E.; Sinha, Sameer; Callan, E. Megan; Akpunonu, Peter (July 2010). "A statewide prescription monitoring program affects emergency department prescribing behaviors". Annals of Emergency Medicine. 56 (1): 19–23.e1–3. doi:10.1016/j.annemergmed.2009.12.011. ISSN   1097-6760. PMID   20045578.
  9. 1 2 3 Finley, Erin P.; Garcia, Ashley; Rosen, Kristen; McGeary, Don; Pugh, Mary Jo; Potter, Jennifer Sharpe (20 June 2017). "Evaluating the impact of prescription drug monitoring program implementation: a scoping review". BMC Health Services Research. 17 (1): 420. doi: 10.1186/s12913-017-2354-5 . PMC   5477729 . PMID   28633638.
  10. Whalen v. Roe , 429 U.S. 589 (1977). PD-icon.svg This article incorporates public domain material from this U.S government document.
  11. 1 2 Briefing on PDMP Effectiveness. (2014). In Prescription Drug Monitoring Program Center of Excellence At Brandeis (p. 13). Brandeis University .
  12. Thielking, M., Ross, C., Branswell, H., Hogan, A., & Associated Press. (2017, March 7). Missouri is the only state not tracking prescription drug use. Here’s why. Retrieved January 24, 2019, from https://www.statnews.com/2017/03/07/missouri-prescription-drug-database/
  13. "Governor Parson Signs SB 63: Creating Statewide Prescription Drug Monitoring Program in Missouri | Governor Michael L. Parson". governor.mo.gov. Retrieved 2022-01-20.
  14. "Integrating & Expanding Prescription Drug Monitoring Program Data: Lessons from Nine States" (PDF). National Center for Injury Prevention and Control. February 2017.
  15. 1 2 Szalavitz, Maia. "A Drug Addiction Risk Algorithm and Its Grim Toll on Chronic Pain Sufferers". Wired. ISSN   1059-1028 . Retrieved 2022-01-20.
  16. Wang, Lucy Xiaolu (27 May 2021). "The complementarity of drug monitoring programs and health IT for reducing opioid-related mortality and morbidity". Health Economics. 30 (9): 2026–2046. doi:10.1002/hec.4360. PMID   34046967. S2CID   235233087.
  17. Hwang, Catherine S.; Turner, Lydia W.; Kruszewski, Stefan P.; Kolodny, Andrew; Alexander, G. Caleb (2016). "Primary Care Physicians' Knowledge And Attitudes Regarding Prescription Opioid Abuse and Diversion". The Clinical Journal of Pain. 32 (4): 279–284. doi:10.1097/ajp.0000000000000268. PMID   26102320. S2CID   6019620.
  18. Pharmacist's Manual. (n.d.). Retrieved from https://www.deadiversion.usdoj.gov/pubs/manuals/pharm2/pharm_content.htm Archived 2019-10-17 at the Wayback Machine
  19. 1 2 Siegel, Zachary (June 2022). "In a World of Stigma and Bias, Can a Computer Algorithm Really Predict Overdose Risk?". Annals of Emergency Medicine. 79 (6): A16–A19. doi: 10.1016/j.annemergmed.2022.04.006 . S2CID   248789032.
  20. 1 2 Beaulieu et al. 2021, p. 5.
  21. 1 2 3 Szalavitz 2021, p. 41.
  22. Szalavitz 2021, p. 40.
  23. Romo, Vanessa (2018-05-08). "Walmart Will Implement New Opioid Prescription Limits By End Of Summer". NPR . Retrieved 2021-10-06.
  24. 1 2 Oliva 2020, p. 847.
  25. Oliva 2020, p. 848.
  26. Fink, David S.; Schleimer, Julia P.; Sarvet, Aaron; Grover, Kiran K.; Delcher, Chris; Castillo-Carniglia, Alvaro; Kim, June H.; Rivera-Aguirre, Ariadne E.; Henry, Stephen G.; Martins, Silvia S.; Cerdá, Magdalena (8 May 2018). "Association Between Prescription Drug Monitoring Programs and Nonfatal and Fatal Drug Overdoses". Annals of Internal Medicine. 168 (11): 783–790. doi:10.7326/M17-3074. PMC   6015770 . PMID   29801093.

Further reading